Meridian Bioscience Balance Sheet 2011-2026 | VIVO

Annual Balance Sheet Meridian Bioscience

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-54.6 M	12.2 M	17.1 M	13.4 M	-9.58 M	-2.42 M	11.1 M	-50 M	-43 M	-44.3 M	-31.6 M	-23.6 M
Long Term Debt	25 M	60 M	68.8 M	75.8 M	44.9 M	50.1 M	54.6 M	-	-	-	-	-
Long Term Debt Current	1.83 M	1.99 M	1.79 M	-	5.25 M	4.5 M	3.75 M	-	-	-	-	-
Total Non Current Liabilities	37.1 M	74.3 M	105 M	114 M	51.8 M	57.3 M	62.8 M	2.16 M	2.16 M	-	171 K	1.7 M
Total Current Liabilities	58 M	47.2 M	52.5 M	20.9 M	24.2 M	22.9 M	22.6 M	15.3 M	13.7 M	21.7 M	18.5 M	15.3 M
Total Liabilities	-	-	-	135 M	76 M	80.2 M	85.4 M	17.4 M	15.9 M	21.7 M	18.6 M	17 M
Retained Earnings	223 M	181 M	109 M	63.1 M	49.6 M	46.9 M	49.6 M	51.1 M	48.9 M	46.9 M	40.2 M	38.1 M
Total Assets	463 M	450 M	405 M	325 M	251 M	250 M	252 M	183 M	177 M	177 M	161 M	155 M
Cash and Cash Equivalents	81.5 M	49.8 M	53.5 M	62.4 M	59.8 M	57.1 M	47.2 M	50 M	43 M	44.3 M	31.6 M	23.6 M
Book Value	463 M	450 M	405 M	191 M	175 M	170 M	166 M	166 M	161 M	155 M	143 M	139 M
Total Shareholders Equity	368 M	328 M	248 M	191 M	175 M	170 M	166 M	166 M	161 M	155 M	143 M	139 M

All numbers in USD currency

Quarterly Balance Sheet Meridian Bioscience

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	25 M	25 M	-	25 M	50 M	60 M	50 M	60 M	58.8 M	68.8 M	68.8 M	68.8 M	75.8 M	75.8 M	75.8 M	75.8 M	43.4 M	44.9 M	44.9 M	44.9 M	49 M	50.1 M	50.1 M	50.1 M	53.5 M	54.6 M	54.6 M	54.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	37.6 M	37.1 M	-	40.7 M	63.5 M	74.3 M	87.7 M	74.3 M	91.2 M	105 M	105 M	105 M	106 M	114 M	114 M	114 M	50.5 M	51.8 M	51.8 M	51.8 M	55.6 M	57.3 M	57.3 M	57.3 M	63.3 M	63 M	62.8 M	62.8 M	2.13 M	2.16 M	2.16 M	2.16 M	2.04 M	2.16 M	2.16 M	2.16 M	-	2.09 M	-	-	-	-	-	-	-	-	-	-
Retained Earnings	193 M	223 M	-	225 M	196 M	181 M	174 M	181 M	136 M	109 M	109 M	109 M	65.9 M	63.1 M	63.1 M	63.1 M	52.3 M	49.5 M	49.5 M	49.5 M	47.9 M	46.9 M	46.9 M	46.9 M	47.5 M	49.6 M	49.6 M	49.6 M	51.5 M	51.1 M	51.1 M	51.1 M	48.4 M	48.9 M	48.9 M	48.9 M	46.4 M	46.9 M	46.9 M	46.9 M	33 M	40.2 M	40.2 M	40.2 M	36.8 M	38.1 M	38.1 M	38.1 M
Total Assets	457 M	463 M	-	472 M	459 M	450 M	447 M	450 M	424 M	405 M	405 M	405 M	338 M	325 M	325 M	325 M	250 M	251 M	251 M	251 M	252 M	250 M	250 M	250 M	250 M	252 M	252 M	252 M	186 M	183 M	183 M	183 M	177 M	177 M	177 M	177 M	175 M	177 M	177 M	177 M	157 M	161 M	161 M	161 M	155 M	155 M	155 M	155 M
Cash and Cash Equivalents	74.1 M	81.5 M	-	76.5 M	72.7 M	49.8 M	70 M	49.8 M	63.2 M	53.5 M	53.5 M	63.2 M	68.6 M	62.4 M	62.4 M	62.4 M	61.5 M	59.8 M	59.8 M	61.5 M	54.7 M	57.1 M	57.1 M	54.7 M	49.3 M	47.2 M	47.2 M	49.3 M	53.4 M	50 M	50 M	53.4 M	49.5 M	43 M	43 M	49.5 M	43.7 M	44.3 M	44.3 M	43.7 M	33.1 M	31.6 M	31.6 M	33.1 M	26.2 M	23.6 M	23.6 M	26.2 M
Book Value	457 M	463 M	-	472 M	459 M	450 M	447 M	450 M	424 M	405 M	405 M	405 M	338 M	325 M	325 M	325 M	250 M	251 M	251 M	251 M	252 M	250 M	250 M	250 M	250 M	252 M	252 M	252 M	186 M	183 M	183 M	183 M	177 M	177 M	177 M	177 M	175 M	177 M	177 M	177 M	157 M	161 M	161 M	161 M	155 M	155 M	155 M	155 M
Total Shareholders Equity	341 M	368 M	-	375 M	345 M	328 M	322 M	345 M	279 M	248 M	279 M	279 M	197 M	191 M	197 M	197 M	179 M	175 M	179 M	179 M	173 M	170 M	170 M	173 M	166 M	166 M	166 M	166 M	169 M	166 M	166 M	166 M	161 M	161 M	161 M	161 M	157 M	155 M	155 M	155 M	138 M	143 M	143 M	143 M	138 M	139 M	139 M	139 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Meridian Bioscience, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis

Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability.
Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer	Price	% 24h	Market Cap	Country
RadNet RDNT	$ 56.78	-4.44 %	$ 4.27 B	USA
Centogene N.V. CNTG	-	-6.23 %	$ 30.6 M	Germany
Soleno Therapeutics SLNO	$ 30.52	-4.12 %	$ 1.55 B	USA
Enzo Biochem ENZ	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	-	-	$ 19.8 B	USA
Akumin AKU	-	-17.87 %	$ 25.9 M	Canada
Neuronetics STIM	$ 1.4	4.89 %	$ 92.3 M	USA
Sotera Health Company SHC	$ 13.26	-2.1 %	$ 3.77 B	USA
Check-Cap Ltd. CHEK	-	-	$ 9.42 M	Israel
Biodesix BDSX	$ 14.18	-2.91 %	$ 1.84 B	USA
Heska Corporation HSKA	-	-	$ 1.31 B	USA
Oxford Immunotec Global PLC OXFD	-	-	$ 562 M	Britain
BioNano Genomics BNGO	$ 1.16	0.87 %	$ 6.32 M	USA
Trinity Biotech plc TRIB	$ 0.6	-2.18 %	$ 61.9 M	Irlanda
Twist Bioscience Corporation TWST	-	-	$ 2.68 B	USA
DermTech DMTK	-	-11.32 %	$ 2.94 M	USA
Aspira Women's Health AWH	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	-	-61.36 %	$ 2.46 M	USA
Global Cord Blood Corporation CO	-	-	$ 399 M	China
Fluidigm Corporation FLDM	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-	0.12 %	$ 80.1 M	China
HTG Molecular Diagnostics HTGM	-	-20.0 %	$ 1.06 M	USA
Castle Biosciences CSTL	$ 23.99	-2.87 %	$ 666 M	USA
PRA Health Sciences, Inc. PRAH	-	-	$ 10.7 B	USA
Charles River Laboratories International CRL	$ 158.77	-3.85 %	$ 7.87 B	USA
Quest Diagnostics Incorporated DGX	$ 195.86	-1.16 %	$ 21.7 B	USA
Organovo Holdings ONVO	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	-	-16.95 %	$ 1.54 M	USA
DarioHealth Corp. DRIO	$ 8.45	-	$ 33.7 M	Israel
Waters Corporation WAT	$ 290.62	-3.31 %	$ 17.3 B	USA
Biocept BIOC	-	-13.05 %	$ 7.29 M	USA
PerkinElmer PKI	-	-0.91 %	$ 14.7 B	USA
Invitae Corporation NVTA	-	-	$ 21.2 M	USA
Interpace Biosciences IDXG	$ 1.68	-2.89 %	$ 7.37 M	USA
IQVIA Holdings IQV	$ 164.81	-2.71 %	$ 28.3 B	USA
Motus GI Holdings MOTS	-	-34.28 %	$ 263 K	Israel
QIAGEN N.V. QGEN	-	-	$ 10.6 B	Niderland
Neogen Corporation NEOG	$ 8.79	-3.93 %	$ 1.91 B	USA
Chembio Diagnostics CEMI	-	0.22 %	$ 16.8 M	USA
Personalis PSNL	$ 6.41	-12.43 %	$ 380 M	USA
Laboratory Corporation of America Holdings LH	$ 266.15	-0.83 %	$ 22.1 B	USA
Senseonics Holdings SENS	$ 6.45	-1.68 %	$ 269 M	USA
Psychemedics Corporation PMD	-	-1.84 %	$ 15.3 M	USA
Precipio PRPO	$ 25.64	-5.75 %	$ 33.3 M	USA
CareDx, Inc CDNA	$ 16.82	-3.72 %	$ 896 M	USA
Quotient Limited QTNT	-	-11.32 %	$ 1.1 M	Schweiz
Syneos Health SYNH	-	-	$ 4.46 B	USA
Renalytix AI plc RNLX	-	5.66 %	$ 22.7 M	Britain
VolitionRx Limited VNRX	$ 0.2	1.08 %	$ 19.2 M	Singapore

Meridian Bioscience Balance Sheet 2011-2026 | VIVO

Annual Balance Sheet Meridian Bioscience

Net Debt

Long Term Debt

Long Term Debt Current

Total Non Current Liabilities

Total Current Liabilities

Total Liabilities

Retained Earnings

Total Assets

Cash and Cash Equivalents

Book Value

Total Shareholders Equity